New radiation schedule could cut treatment time for throat cancer patients

NCT ID NCT06080503

Recruiting now Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial compares a new, shorter radiation schedule (LT-SABR, given over 1-2 weeks) to standard radiation (over 5-6 weeks) for early-stage laryngeal cancer. The goal is to see if the shorter schedule causes fewer severe side effects in the first 3 months. About 67 adults with stage 0-II glottic laryngeal cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (LT-SABR or IMRT)
What this could lead to: If successful, this could offer a shorter, more convenient radiation schedule with fewer acute side effects for people with early-stage laryngeal cancer.
What could go wrong: This is a small, early-phase study (67 participants) comparing two radiation approaches, so results may not apply broadly. The higher-dose schedule could also increase long-term risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glottis squamous cell carcinoma laryngeal carcinoma laryngeal disorder laryngeal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARYNGEAL CARCINOMA

Contacts and locations

Locations

University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.